ABSTRACT
BACKGROUND: Approximately 70% of breast cancer patients have residual disease after neoadjuvant chemotherapy. This study was designed to determine whether breast cancer cells with stemlike properties are present in residual disease after neoadjuvant chemotherapy and whether they exhibit oncogenic mutations. The presence of breast cancer cells with stemlike properties with specific mutations may help explain the poor prognosis associated with residual disease. METHODS: A total of 68 breast cancer specimens were collected at the time of mastectomy or lumpectomy. A total of 44 were chemotherapy naïve and 24 were collected as residual disease after neoadjuvant chemotherapy. Tumor cells were collected by fluorescence-activated cell sorting, with breast cancer cells with stemlike properties specifically identified using breast stem cell associated antibodies. Whole tumor specimens and fluorescence-activated cell sorting breast cancer cells with stemlike properties were analyzed for genetic mutations, including PIK3CA. RESULTS: Breast cancer cells with stemlike properties, demonstrating EpCAM-positive, CD44-positive, CD49f±, CD24± expression were present in chemotherapy-naïve tumors and residual disease. In both chemotherapy-naïve and residual disease specimens the highest frequency of PIK3CA mutations were detected in CD49f-CD24+ BCSCs (39% and 33%, respectively). PIK3CA mutations were detected in all stages of breast cancer (35%), in both chemotherapy naïve (39%) and residual disease (29%) and in both estrogen receptor positive (41%) and negative tumors (14%) (P = ns). Various PIK3CA mutations were identified in chemotherapy-naïve specimens versus residual disease specimens in both patient-paired and unpaired breast cancers. CONCLUSION: Breast cancer cells with stemlike properties with mutations in PIK3CA were present in chemotherapy-naïve breast cancers and residual disease after neoadjuvant chemotherapy. These results demonstrate that neoadjuvant chemotherapy does not completely eradicate PIK3CA-defective breast cancer cells with stemlike properties. Although these findings may help explain the poor clinical outcomes in patients with residual disease, they also identify breast cancer cells with stemlike-property targets for therapies.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/pharmacology , Breast Neoplasms/therapy , Breast/pathology , Neoplastic Stem Cells/drug effects , Adult , Aged , Aged, 80 and over , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Biomarkers, Tumor/genetics , Biomarkers, Tumor/metabolism , Breast/drug effects , Breast/surgery , Breast Neoplasms/pathology , Class I Phosphatidylinositol 3-Kinases/genetics , Class I Phosphatidylinositol 3-Kinases/metabolism , Female , Humans , Mastectomy , Middle Aged , Mutation , Neoadjuvant Therapy/methods , Neoplasm, Residual , Neoplastic Stem Cells/metabolism , Treatment OutcomeSubject(s)
Education/trends , Neoplasms/psychology , Writing , Adult , Creativity , Humans , Young AdultABSTRACT
Risk or presence of metastasis in medulloblastoma causes substantial treatment-related morbidity and overall mortality. Through the comparison of cytokines and growth factors in the cerebrospinal fluid (CSF) of metastatic medulloblastoma patients with factors also in conditioned media of metastatic MYC amplified medulloblastoma or leptomeningeal cells, we were led to explore the bioactivity of IGF1 in medulloblastoma by elevated CSF levels of IGF1, IGF-sequestering IGFBP3, IGFBP3-cleaving proteases (MMP and tPA), and protease modulators (TIMP1 and PAI-1). IGF1 led not only to receptor phosphorylation but also accelerated migration/adhesion in MYC amplified medulloblastoma cells in the context of appropriate matrix or meningothelial cells. Clinical correlation suggests a peri-/sub-meningothelial source of IGF-liberating proteases that could facilitate leptomeningeal metastasis. In parallel, studies of key factors responsible for cell autonomous growth in MYC amplified medulloblastoma prioritized IGF1R inhibitors. Together, our studies identify IGF1R as a high value target for clinical trials in high risk medulloblastoma.
Subject(s)
Cerebellar Neoplasms/cerebrospinal fluid , Medulloblastoma/cerebrospinal fluid , Meningeal Neoplasms/cerebrospinal fluid , Receptors, Somatomedin/metabolism , Adolescent , Antineoplastic Agents/pharmacology , Biomarkers, Tumor/antagonists & inhibitors , Biomarkers, Tumor/cerebrospinal fluid , Biomarkers, Tumor/genetics , Case-Control Studies , Cell Adhesion , Cell Line, Tumor , Cell Movement , Cell Proliferation , Cerebellar Neoplasms/drug therapy , Cerebellar Neoplasms/pathology , Child , Drug Screening Assays, Antitumor , Female , Gene Expression , Humans , Inhibitory Concentration 50 , Insulin-Like Growth Factor Binding Protein 3/cerebrospinal fluid , Insulin-Like Growth Factor Binding Protein 3/genetics , Insulin-Like Growth Factor I/cerebrospinal fluid , Insulin-Like Growth Factor I/genetics , Male , Matrix Metalloproteinase 9/cerebrospinal fluid , Matrix Metalloproteinase 9/genetics , Medulloblastoma/drug therapy , Medulloblastoma/secondary , Meningeal Neoplasms/drug therapy , Meningeal Neoplasms/secondary , Molecular Targeted Therapy , Plasminogen Activator Inhibitor 1/cerebrospinal fluid , Plasminogen Activator Inhibitor 1/genetics , Receptor, IGF Type 1 , Receptors, Somatomedin/antagonists & inhibitors , Receptors, Somatomedin/genetics , Tissue Inhibitor of Metalloproteinase-1/cerebrospinal fluid , Tissue Inhibitor of Metalloproteinase-1/geneticsABSTRACT
INTRODUCTION: Cancers are believed to adapt to continual changes in glucose and oxygen availability by relying almost exclusively on glycolytic metabolism for energy (i.e. the Warburg effect). The process by which breast cancers sustain growth in avascular tissue is thought to be mediated via aberrant hypoxia response with ensuing shifts in glycolytic metabolism. Given their role in initiating and perpetuating tumors, we sought to determine whether breast cancer stem and progenitor cells play an instrumental role in this adaptive metabolic response. METHODS: Breast cancer stem/progenitor cells were isolated from invasive ductal carcinomas, and benign stem cells (SC) were isolated from reduction mammoplasty tissues. Relative expression of 33 genes involved in hypoxia and glucose metabolism was evaluated in flow cytometrically isolated stem and progenitor cell populations. Significance between cohorts and cell populations was determined using Student's 2-tailed t test. RESULTS: While benign stem/progenitor cells exhibited few significant inter-group differences in expression of genes involved in hypoxia regulation or glucose metabolism, breast cancer stem/progenitor cells demonstrated significant inter-group variability. Breast cancer stem/progenitor cells adapted to microenvironments through changes in stem cell numbers and transcription of glycolytic genes. One of four breast cancer stem/progenitor cells subpopulations exhibited an aerobic glycolysis gene expression signature. This subpopulation comprises the majority of the tumor and therefore best reflects invasive ductal carcinoma tumor biology. Although PI3K/AKT mutations are associated with increased proliferation of breast cancer cells, mutations in breast cancer stem/progenitor cells subpopulations did not correlate with changes in metabolic gene expression. CONCLUSIONS: The adaptive capacity of breast cancer stem/progenitor cells may enable tumors to survive variable conditions encountered during progressive stages of cancer growth.
Subject(s)
Breast Neoplasms/genetics , Glycolysis , Neoplastic Stem Cells/metabolism , Transcriptome , Breast Neoplasms/metabolism , Breast Neoplasms/pathology , Cells, Cultured , Female , Humans , MCF-7 Cells , Phosphatidylinositol 3-Kinases/genetics , Phosphatidylinositol 3-Kinases/metabolism , Proto-Oncogene Proteins c-akt/genetics , Proto-Oncogene Proteins c-akt/metabolismABSTRACT
Leptomeningeal metastasis is a cause of morbidity and mortality in medulloblastoma, but the understanding of molecular mechanisms driving this process is nascent. In this study, we examined the secretory chemokine profile of medulloblastoma cells (DAOY) and a meningothelial cell line (BMEN1). Conditioned media (CM) of meningothelial cells increased adhesion, spreading and migration of medulloblastoma. VEGFA was identified at elevated levels in the CM from BMEN1 cells (as compared to DAOY CM); however, recombinant VEGFA alone was insufficient to enhance medulloblastoma cell migration. In addition, bevacizumab, the VEGFA scavenging monoclonal antibody, did not block the migratory phenotype induced by the CM. These results reveal that paracrine factors secreted by meningothelial cells can influence migration and adherence of medulloblastoma tumor cells, but VEGFA may not be a specific target for therapeutic intervention in this context.
Subject(s)
Chemokines/immunology , Chemokines/metabolism , Medulloblastoma/immunology , Meninges/immunology , Meninges/metabolism , Meninges/pathology , Vascular Endothelial Growth Factor A/immunology , Cell Communication/immunology , Cell Line, Tumor , Cell Movement/immunology , Humans , Medulloblastoma/pathologyABSTRACT
A novel series of pyridyl carboxamide-based CCR5 inhibitors was designed, synthesized, and demonstrated to be highly potent against HIV-1 infection in both HOS and PBL assays. Attempts to evaluate this series of compounds in a rat PK model revealed its instability in rat plasma. A hypothesis for this liability was proposed, and strategies to overcome this issue were pursued, leading to discovery of highly potent 40 and 41, which featured dramatically improved rat PK profiles.
Subject(s)
Anti-HIV Agents/pharmacokinetics , CCR5 Receptor Antagonists , Carboxylic Acids/pharmacokinetics , Amides/chemistry , Animals , Anti-HIV Agents/blood , Anti-HIV Agents/chemistry , Carboxylic Acids/blood , Carboxylic Acids/chemistry , Drug Discovery , RatsABSTRACT
We recently described ( J. Med. Chem. 2008 , 51 , 6538 - 6546 ) a novel class of CCR5 antagonists with strong anti-HIV potency. Herein, we detail SAR converting leads 1 and 2 to druglike molecules. The pivotal structural motif enabling this transition was the secondary sulfonamide substituent. Further fine-tuning of the substituent pattern in the sulfonamide paved the way to enhancing potency and bioavailability and minimizing hERG inhibition, resulting in discovery of clinical compound 122 (GSK163929).
Subject(s)
Anti-HIV Agents/chemistry , Anti-HIV Agents/pharmacology , Azabicyclo Compounds/chemistry , Azabicyclo Compounds/pharmacology , CCR5 Receptor Antagonists , Ether-A-Go-Go Potassium Channels/antagonists & inhibitors , HIV-1/drug effects , Piperidines/chemistry , Piperidines/pharmacology , Animals , Anti-HIV Agents/chemical synthesis , Anti-HIV Agents/metabolism , Area Under Curve , Azabicyclo Compounds/chemical synthesis , Azabicyclo Compounds/metabolism , Benzimidazoles , Dogs , Drug Design , Ether-A-Go-Go Potassium Channels/genetics , Ether-A-Go-Go Potassium Channels/metabolism , Haplorhini , Humans , Piperidines/chemical synthesis , Piperidines/metabolism , Rats , Structure-Activity Relationship , Sulfonamides , TropanesABSTRACT
Several series of carbamate, urea and carboxamide-based CCR5 antagonists have been discovered via optimizations at the amine portion of lead compound 2. All compounds were evaluated for their antiviral activities. Lead urea 29 showed good pharmacokinetic properties, justifying further development of this series.
Subject(s)
Amines/chemistry , Anti-HIV Agents/chemistry , CCR5 Receptor Antagonists , HIV-1/drug effects , Phenylurea Compounds/chemistry , Sulfonamides/chemistry , Urea/analogs & derivatives , Animals , Anti-HIV Agents/chemical synthesis , Anti-HIV Agents/pharmacokinetics , Cell Line, Tumor , Drug Evaluation, Preclinical , Humans , Phenylurea Compounds/chemical synthesis , Phenylurea Compounds/pharmacokinetics , Rats , Rats, Sprague-Dawley , Receptors, CCR5/metabolism , Structure-Activity Relationship , Sulfonamides/chemical synthesis , Sulfonamides/pharmacokinetics , Urea/chemical synthesis , Urea/pharmacokinetics , Virus Replication/drug effectsABSTRACT
Modification of the acyl moiety in the CCR5 lead molecule 2 led to identification of several new classes of CCR5 antagonists. Antiviral activity and pharmacokinetic properties of the synthesized compounds were evaluated. Structure-activity relationship (SAR) derived from these studies further guided the optimization efforts, ultimately leading to the discovery of 36 with an acceptable drug-like profile.
Subject(s)
Anti-HIV Agents/chemistry , CCR5 Receptor Antagonists , HIV-1/drug effects , Urea/analogs & derivatives , Animals , Anti-HIV Agents/chemical synthesis , Anti-HIV Agents/pharmacokinetics , Cell Line, Tumor , Dogs , Drug Evaluation, Preclinical , Haplorhini , Humans , Pyridines/chemistry , Rats , Receptors, CCR5/metabolism , Structure-Activity Relationship , Urea/chemical synthesis , Urea/pharmacokinetics , Virus Replication/drug effectsABSTRACT
We report the application of phosphoramidate pronucleotide (ProTide) technology to the antiviral agent carbocyclic L-d4A (L-Cd4A). The phenyl methyl alaninyl parent ProTide of L-Cd4A was prepared by Grignard-mediated phosphorochloridate reaction and resulted in a compound with significantly improved anti-HIV (2600-fold) and HBV activity. We describe modifications of the aryl, ester, and amino acid regions of the ProTide and how these changes affect antiviral activity and metabolic stability. Separate and distinct SARs were noted for HIV and HBV. Additionally, ProTides were prepared from the D-nucleoside D-Cd4A and the dideoxy analogues L-CddA and D-CddA. These compounds showed more modest potency improvements over the parent drug. In conclusion, the ProTide approach is highly successful when applied to L-Cd4A with potency improvements in vitro as high as 9000-fold against HIV. With a view to preclinical candidate selection we carried out metabolic stability studies using cynomolgus monkey liver and intestinal S9 fractions.
Subject(s)
Adenosine/analogs & derivatives , Adenosine/chemical synthesis , Antiviral Agents/chemical synthesis , Organophosphorus Compounds/chemical synthesis , Adenosine/pharmacology , Animals , Anti-HIV Agents/chemical synthesis , Anti-HIV Agents/pharmacology , Antiviral Agents/pharmacology , Cell Line , HIV-1/drug effects , HIV-2/drug effects , Hepatitis B virus/drug effects , Humans , In Vitro Techniques , Intestinal Mucosa/metabolism , Liver/metabolism , Nucleotides/chemical synthesis , Nucleotides/pharmacology , Organophosphorus Compounds/pharmacology , Structure-Activity RelationshipABSTRACT
A series of [1-aryl-1H-pyrazolo[3,4-d]pyrimidin-4-yl]arylhydrazones were discovered as novel inhibitors glycogen synthase kinase-3 (GSK-3). Based on initial modeling a detailed SAR was constructed. Modification of the interior binding aryl ring (Ar(1)) determined this to be a tight binding region with little room for modification. As predicted from the model, a large variety of modifications could be incorporated into the hydrazone aryl ring. This work led to GSK-3 inhibitors in the low nano-molar range.
